Spectrum Pharmaceuticals, Inc.

Informe acción NasdaqCM:SPPI

Capitalización de mercado: US$209.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Spectrum Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Spectrum Pharmaceuticals de 67.3% y 35.5% respectivamente, mientras que el BPA crecerá en un 75.4% al año.

Información clave

67.3%

Tasa de crecimiento de los beneficios

75.36%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.4%
Tasa de crecimiento de los ingresos35.5%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización25 Jul 2023

Actualizaciones recientes sobre el crecimiento futuro

Artículo de análisis • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...

Recent updates

Artículo de análisis • May 14

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Shareholders in Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) may be thrilled to learn that the analysts have just...
Artículo de análisis • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...
Seeking Alpha • Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
Artículo de análisis • Sep 16

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 09

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection. The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils). SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years. The company plans to commercially launch the injection in Q4. Shares of SPPI have fallen 18.2% YTD.
Seeking Alpha • Aug 21

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

We are circling back on a small biopharma named Spectrum Pharmaceuticals for the first time in a year and a half today. Spectrum has turned into a soap opera since then with two departures from the C-Suite, a CRL, and a significant workforce reduction. However, the company still is pushing two compounds towards potential FDA approval this year. An investment analysis follows in the paragraphs below. "Even as a solid rock is unshaken by the wind, so are the wise unshaken by praise or blame."― Dhammapada We last posted an article on Spectrum Pharmaceuticals (SPPI) back in March of 2021. At that time, we declined any investment recommendation on the shares but did promise to circle back on this name as its story developed. The company reported second-quarter results earlier this month and I have gotten a question or two from Seeking Alpha followers recently. Therefore, we will revisit this small biopharma company via the analysis below. Seeking Alpha Company Overview: Spectrum Pharmaceuticals focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. The company is headquartered just outside of Las Vegas. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $250 million. Recent Developments: The company has been a non-stop soap opera since we last looked in on it. Its primary asset is ROLONTIS (eflapegrastim). Spectrum had submitted a marketing application on it for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. This candidate has had a rocky ride, to say the least, towards FDA approval. First, the inspection of the manufacturing facility where ROLONTIS was to be made in South Korea by partner Hanmi was delayed thanks to the pandemic. March Company Presentation Then in August of 2021, the FDA slapped Spectrum's Biologics License Application or BLA with a Complete Response Letter or CRL. The CRL cited deficiencies related to manufacturing and indicated that a re-inspection will be necessary. Then in December of last year, the company announced its CEO was retiring which was followed by resignation of its CFO in February of this year. In between those management losses, Spectrum announced a restructuring that resulted in approximately 30% of its workforce being let go. The company also halted development of early-stage drug candidates to focus solely on pushing poziotinib and ROLONTIS across the finish line. These measures were projected to reduce annual cash burn by 20% to 25% and push the company's 'cash runway' into 2023. The company did resubmit its BLA for ROLONTIS in April and the FDA is scheduled to make a decision on its application on September 9th. January 2021 Company Presentation The FDA completed re-inspection of the manufacturing facility for ROLONTIS in August. Chemo-induced neutropenia impacts just over one million individuals in the United States. ROLONTIS would be the first drug in its class approved for this indication since Neulasta got the green light from the FDA in 2002. March Company Presentation March Company Presentation The approval path for poziotinib has been much smoother to this point. The compound is targeting patients with previously treated, locally advanced or metastatic non-small cell lung cancer, harboring HER2 exon 20 insertion mutations. This drug candidate is an orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Poziotinib has fast track designation and is on an accelerated approval pathway for this indication. The NDA was submitted some ago has a PDUFA date of November 24th of this year. It is important to note Poziotinib has a much smaller potential market than ROLONTIS and the company will have to demonstrate the compound has an overall risk benefit and clinical relevance based on its 'ZENITH' study to the FDA to garner approval. A randomized confirmatory trial is currently ongoing. A critical phase 2 trial in 2nd line NSCLC patients with EGFR exon 20 mutations around Poziotinib did not meet its primary endpoint of ORR in one of its cohorts early in 2020. Analyst Commentary & Balance Sheet: Since second quarter results posted, B. Riley Financial ($4 price target), H.C. Wainwright ($10 price target) and JMP Securities ($4 price target) have all reiterated Buy ratings on SPPI.
Seeking Alpha • Aug 10

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (+60.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 38% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.
Artículo de análisis • Jun 04

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 25

Spectrum Pharmaceuticals: Some Last Words

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize.
Artículo de análisis • Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more.
Seeking Alpha • Jul 29

Spectrum's Big Approval: Any Day Now

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market.
Artículo de análisis • May 31

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Feb 12

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 21

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

A look at the shareholders of Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) can tell us which group is most powerful...

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:SPPI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202520197361414
12/31/20241271418365
12/31/202373-18-2123
3/31/202326-68-88-88N/A
12/31/202210-78-97-97N/A
9/30/2022N/A-106-102-102N/A
6/30/2022N/A-117-109-109N/A
3/31/2022N/A-138-115-115N/A
12/31/2021N/A-158-120-119N/A
9/30/2021N/A-169-121-122N/A
6/30/2021N/A-184-127-125N/A
3/31/2021N/A-166-127-123N/A
12/31/2020N/A-171-127-122N/A
9/30/2020N/A-162-127-120N/A
6/30/2020N/A-140-131-119N/A
3/31/2020N/A-136-138-128N/A
12/31/2019N/A-135-144-135N/A
9/30/2019N/A-148-127-116N/A
6/30/2019N/A-191-103-100N/A
3/31/2019N/A-147-79-76N/A
12/31/2018N/A-127-65-62N/A
9/30/201829-102-63-63N/A
6/30/201865-51-59-59N/A
3/31/201899-87-46-45N/A
12/31/2017N/A-101-39-39N/A
9/30/2017135-81-30-29N/A
6/30/2017132-81-36-36N/A
3/31/2017132-84-54-54N/A
12/31/2016146-70N/A-40N/A
9/30/2016162-55N/A-34N/A
6/30/2016157-56N/A-30N/A
3/31/2016168-35N/A5N/A
12/31/2015163-53N/A7N/A
9/30/2015164-50N/A15N/A
6/30/2015183-42N/A34N/A
3/31/2015185-44N/A31N/A
12/31/2014187-46N/A-4N/A
9/30/2014176-82N/A-7N/A
6/30/2014171-78N/A-30N/A
3/31/2014157-84N/A-64N/A
12/31/2013156-62N/A-2N/A
9/30/2013184-15N/A-2N/A
6/30/201321114N/A30N/A
3/31/201324742N/A67N/A
12/31/201226894N/A72N/A
9/30/201225195N/A75N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SPPI sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.1%).

Beneficios vs. Mercado: Se prevé que SPPI sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que SPPI sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (35.5% al año) de SPPI crezcan más rápidamente que los del mercado US (11.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (35.5% al año) de SPPI crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SPPI se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/08/02 19:45
Precio de las acciones al final del día2023/07/31 00:00
Beneficios2023/03/31
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Spectrum Pharmaceuticals, Inc. está cubierta por 9 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.
Reni BenjaminCitizens JMP Securities, LLC